🔎 Trials Near Me

Beranda › Kanker Payudara › Ohio › Cleveland

Uji klinis Kanker Payudara di Cleveland, OH

35 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Cleveland (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Vanguard Study: Testing a New Way to Screen for Cancer

Menerima pesertaSukarelawan sehat diterima
  • Louis Stokes Cleveland VA Medical Center, Cleveland
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06995898

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Menerima pesertaFase 1/2
  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Menerima pesertaFase 2
  • Cleveland Clinic - Oncology Department, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

Study of AVZO-021 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Avenzo Therapeutics Recruiting Site, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05867251

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06618287

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Menerima peserta
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Menerima pesertaFase 3
  • University Hospitals Cleveland Medical Center, Cleveland
  • Fairview Hospital, Cleveland
  • Cleveland Clinic - Hillcrest Hospital, Mayfield Heights · 12 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07174336

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Menerima pesertaFase 1/2
  • UH Cleveland Medical Center, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726

Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer

Menerima peserta
  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland
Usia 18 hingga 65 · Wanita · Diperbarui 15 Sep 2026 · NCT04362826

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Menerima pesertaFase 3
  • MetroHealth, Cleveland
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Menerima pesertaFase 1
  • University Hospital Cleveland Medical Center, Cleveland
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Menerima pesertaFase 1
  • Cleveland Clinic Foundation, Cleveland
Usia 18 hingga 55 · Wanita · Diperbarui 9 Sep 2026 · NCT07310420

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Menerima pesertaFase 3
  • Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • Hillcrest Hospital, Mayfield Heights · 12 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06790693

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Menerima pesertaFase 3
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06072612

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Menerima pesertaFase 3
  • Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • South Pointe Hospital, Warrensville Heights · 9 mi jauhnya
  • dan 1 lainnya
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Menerima pesertaFase 1
  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

Menerima pesertaFase 2
  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06129747

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Menerima pesertaFase 2
  • Case Western Reserve University, Cleveland
Usia 18 hingga 55 · Wanita · Diperbarui 27 Jul 2026 · NCT06184750

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Menerima peserta
  • Case Western Reserve University/University Hospitals Cleveland, Cleveland
Usia 65 ke atas · Wanita · Diperbarui 17 Jul 2026 · NCT05535192

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Menerima pesertaFase 1
  • UHCMC Seidman Cancer Center, Cleveland
Usia 18 ke atas · Wanita · Diperbarui 15 Jul 2026 · NCT05996107

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • UH Cleveland Medical Center, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Menerima pesertaFase 3
  • University Hospitals Seidman Cancer Center, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT05696626

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Menerima pesertaFase 2
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT01042379

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Menerima pesertaFase 3
  • Case Western Reserve University, Cleveland
  • MetroHealth Medical Center, Cleveland
  • Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
  • dan 3 lainnya
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Menerima pesertaFase 1/2
  • Cleveland Clinic, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT05455619

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Menerima pesertaStudi observasional
  • University Hospitals Seidman Cancer Center, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Feb 2026 · NCT05974150

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Cleveland Clinic, Cleveland
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Menerima pesertaStudi observasional
  • Cleveland Clinic Main Campus, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06401421

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi jauhnya
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

The Cancer of the Pancreas Screening-5 CAPS5)Study

Menerima pesertaFase 3
  • Case Comprehensive Cancer Center, Case Western Medical Reserve, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Okt 2025 · NCT02000089

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Menerima pesertaFase 3
  • Case Western Reserve University, Cleveland
  • Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
  • Cleveland Clinic Foundation, Cleveland
  • dan 3 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • Exelixis Clinical Site #7, Cleveland
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Sep 2025 · NCT05932862

Uji klinis Kanker Payudara di kota lain

Studi lain di Cleveland

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.